Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Scott A. Foster, Daniel M. Whalen, Ayşegül Özen, et al.
Cancer Cell (2016) Vol. 29, Iss. 4, pp. 477-493
Open Access | Times Cited: 202

Showing 1-25 of 202 citing articles:

Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Benjamin J. Raphael, Ralph H. Hruban, Andrew J. Aguirre, et al.
Cancer Cell (2017) Vol. 32, Iss. 2, pp. 185-203.e13
Open Access | Times Cited: 1717
Molecular subtypes of pancreatic cancer
Eric A. Collisson, Peter J. Bailey, David K. Chang, et al.
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 4, pp. 207-220
Closed Access | Times Cited: 761
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Andrew M. Waters, Channing J. Der
Cold Spring Harbor Perspectives in Medicine (2017) Vol. 8, Iss. 9, pp. a031435-a031435
Open Access | Times Cited: 733
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Kirsten L. Bryant, Clint A. Stalnecker, Daniel Zeitouni, et al.
Nature Medicine (2019) Vol. 25, Iss. 4, pp. 628-640
Open Access | Times Cited: 574
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Matthew Dankner, April A. N. Rose, Shivshankari Rajkumar, et al.
Oncogene (2018) Vol. 37, Iss. 24, pp. 3183-3199
Closed Access | Times Cited: 464
Targeting Alterations in the RAF–MEK Pathway
Rona Yaeger, Ryan B. Corcoran
Cancer Discovery (2019) Vol. 9, Iss. 3, pp. 329-341
Open Access | Times Cited: 373
Drugging RAS: Know the enemy
Bjoern Papke, Channing J. Der
Science (2017) Vol. 355, Iss. 6330, pp. 1158-1163
Open Access | Times Cited: 352
Accelerating Discovery of Functional Mutant Alleles in Cancer
Matthew T. Chang, Tripti Shrestha Bhattarai, Alison M. Schram, et al.
Cancer Discovery (2017) Vol. 8, Iss. 2, pp. 174-183
Open Access | Times Cited: 346
New perspectives for targeting RAF kinase in human cancer
Zoi Karoulia, Evripidis Gavathiotis, Poulikos I. Poulikakos
Nature reviews. Cancer (2017) Vol. 17, Iss. 11, pp. 676-691
Open Access | Times Cited: 342
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Andrew J. Aguirre, Jonathan A. Nowak, Nicholas D. Camarda, et al.
Cancer Discovery (2018) Vol. 8, Iss. 9, pp. 1096-1111
Open Access | Times Cited: 322
Atropisomerism in Medicinal Chemistry: Challenges and Opportunities
Sean T. Toenjes, Jeffrey L. Gustafson
Future Medicinal Chemistry (2018) Vol. 10, Iss. 4, pp. 409-422
Open Access | Times Cited: 306
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling
Zoi Karoulia, Yang Wu, Tamer A. Ahmed, et al.
Cancer Cell (2016) Vol. 30, Iss. 3, pp. 485-498
Open Access | Times Cited: 185
CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation
Kenji Kashima, Hiroki Kawauchi, Hiromi Tanimura, et al.
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 11, pp. 2288-2297
Open Access | Times Cited: 140
Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches
Punit Saraon, Shivanthy Pathmanathan, Jamie Snider, et al.
Oncogene (2021) Vol. 40, Iss. 24, pp. 4079-4093
Closed Access | Times Cited: 133
Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors
Christopher Arter, Luke Trask, Sarah Ward, et al.
Journal of Biological Chemistry (2022) Vol. 298, Iss. 8, pp. 102247-102247
Open Access | Times Cited: 101
E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers
Hong‐Beom Park, Kwang‐Hyun Baek
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 3, pp. 188736-188736
Closed Access | Times Cited: 98
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Aphrothiti J. Hanrahan, Ziyu Chen, Neal Rosen, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 224-247
Closed Access | Times Cited: 39
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival
Anna M. Varghese, Maria Perry, Joanne F. Chou, et al.
Nature Medicine (2025)
Open Access | Times Cited: 3
Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis
Rikhia Chakraborty, Thomas M. Burke, Oliver Hampton, et al.
Blood (2016) Vol. 128, Iss. 21, pp. 2533-2537
Open Access | Times Cited: 150
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
Angelina V. Vaseva, Devon R. Blake, Thomas S.K. Gilbert, et al.
Cancer Cell (2018) Vol. 34, Iss. 5, pp. 807-822.e7
Open Access | Times Cited: 148
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Ritu Singh, Eileen M. O’Reilly
Drugs (2020) Vol. 80, Iss. 7, pp. 647-669
Open Access | Times Cited: 132
BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
Karisa C. Schreck, Stuart A. Grossman, Christine A. Pratilas
Cancers (2019) Vol. 11, Iss. 9, pp. 1262-1262
Open Access | Times Cited: 125
Targeting the Raf kinases in human cancer: the Raf dimer dilemma
David Durrant, Deborah K. Morrison
British Journal of Cancer (2017) Vol. 118, Iss. 1, pp. 3-8
Open Access | Times Cited: 120
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties
Yijun Gao, Matthew T. Chang, Daniel J. McKay, et al.
Cancer Discovery (2018) Vol. 8, Iss. 5, pp. 648-661
Open Access | Times Cited: 120
Increased autophagy blocks HER2-mediated breast tumorigenesis
Silvia Vega-Rubín-de-Celis, Zhongju Zou, Álvaro F. Fernández, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 16, pp. 4176-4181
Open Access | Times Cited: 119
Page 1 - Next Page

Scroll to top